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RNA interference (RNAi†) is a remarkable endogenous regulatory pathway that can bring
about sequence-specific gene silencing. If harnessed effectively, RNAi could result in a po-
tent targeted therapeutic modality with applications ranging from viral diseases to cancer.
The major barrier to realizing the full medicinal potential of RNAi is the difficulty of deliver-
ing effector molecules, such as small interfering RNAs (siRNAs), in vivo. An effective deliv-
ery strategy for siRNAs must address limitations that include poor stability and non-targeted
biodistribution, while protecting against the stimulation of an undesirable innate immune re-
sponse. The design of such a system requires rigorous understanding of all mechanisms in-
volved. This article reviews the mechanistic principles of RNA interference, its potential, the
greatest challenges for use in biomedical applications, and some of the work that has been
done toward engineering delivery systems that overcome some of the hurdles facing siRNA-
based therapeutics.
MechanisMs of Rnai
In 1998, Fire and Mello uncovered the
world of RNA interference (RNAi) and
revolutionized  the  contemporary  under-
standing  of  gene  regulation  when  they
made the discovery that the silencing ef-
fectors  in  Caenorhabditis  elegans were
double stranded RNAs [1]. Shortly there-
after,  small  interfering  RNAs  (siRNAs)
were discovered in plants [2] and similarly
demonstrated to guide sequence-dependent
endonucleolytic cleavage of the mRNAs
that they regulate in mammalian cells [3,4].
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some, nanoparticle, targetingBy 2001, Elbashir et al. had successfully
used synthetic siRNAs for silencing and de-
termined  the  basic  principles  of  siRNA
structure and RNAi mechanics, providing
the foundation for developing RNAi appli-
cations [5,6]. Since then, selectively silenc-
ing  genes  by  hijacking  the  endogenous
RNAi pathway with synthetic constructs has
become  a  widely  used  technique  for  the
study of gene function, and further, this ap-
proach has shown impressive therapeutic
potential that is expected to be realized in
the near future.
RNAi Machinery
RNAi  can  be  effected  when  short
(~22nt), double-stranded fragments of RNA
— known as small interfering RNAs (siR-
NAs) — are loaded into the RNA-Induced
Silencing  Complex  (RISC),  where  the
strands are separated, and one strand guides
cleavage by Argonaute of target mRNAs in
a  sequence  homology-dependent  manner
[3].
In mammalian cells, siRNAs are pro-
duced via endonucleolytic processing by the
ribonuclease  Dicer  of  exogenously  intro-
duced long, double-stranded RNA [12]. Dicer
is an endonuclease of the RNase III family
(Figure 1); it acts as a “molecular ruler” and
precisely produces RNA duplexes ~21-25 nu-
cleotides in length with characteristic termini.
The 3’ end carries a dinucleotide overhang,
while the 5’ end terminates in a monophos-
phate group [6,7,8,9,12]. The siRNA duplex
length and distinctive ends are necessary fea-
tures for efficient recognition by and integra-
tion  into  the  RISC.  Furthermore,  recent
biochemical studies show that Dicer process-
ing  itself  is  coupled  with  RISC  loading
through the tight association of Dicer with
TRBP (the human immunodeficiency trans
activating response RNA-binding protein)
[10,11].   
The heart of the RISC complex and
principal  executer  of  RNAi-mediated  si-
lencing is the Argonaute protein [13,14].
There are four Argonaute proteins in humans
(AGO 1-4), and silencing by siRNAs is ac-
complished via AGO2 [13]. To bring about
siRNA-mediated  silencing,  AGO2  must
tether the guide siRNA strand, extrude the
passenger strand, and then undergo several
cycles of target mRNA recognition, cleav-
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figure 1. small interfering Rnas (siRnas)
mediate silencing of target genes by
guiding sequence dependent slicing of
their target mRnas. These non-coding, si-
lencing RNAs begin as long double-stranded
RNA (dsRNA) molecules, which are
processed by endonuclease Dicer into short,
active ~21-25 nt constructs. Once generated,
a siRNA duplex is loaded by Dicer, with the
help of RNA-binding protein TRBP, onto Arg-
onaute (AGO2), the heart of the RNA-in-
duced silencing complex (which here is
represented just by AGO2). upon loading,
AGO2 selects the siRNA guide strand, then
cleaves and ejects the passenger strand.
While tethered to AGO2, the guide strand
subsequently pairs with its complementary
target mRNAs long enough for AGO2 to slice
the target. After slicing, the cleaved target
mRNA is released and RISC is recycled,
using the same loaded guide strand for an-
other few rounds of slicing [12].  age, and release while the guide strand re-
mains  bound  (Figure  1)  [12].  Structural
studies revealed some of the mechanisms
underlying  AGO2’s  activity.  AGO2  has
three functional domains, PAZ, MID, and
PIWI, of which PIWI adopts an RNase H
fold and is the powerhouse behind RISC’s
“slicer” activity [15]. For RISC loading,
structural evidence suggests that the charac-
teristic terminal moieties of siRNA serve an-
choring  functions:  the  3’dinucleotide  is
specifically recognized by the PAZ domain
of Argonaute. The overhang burrows deep
into a hydrophobic pocket of the domain,
where the base of the terminal nucleotide
can stack with an aromatic ring of one of the
numerous aromatic residues that line the
pocket [16-18]. Meanwhile, the 5’ phosphate
group inserts between the MID and PIWI
domains, binding to a magnesium ion that
itself is coordinated to the C-terminus of the
protein (Figure 2) [19,21]. For guide-strand
selection, thermodynamic data indicates that
Argonaute selects the guide strand as the one
with the less thermodynamically stable 5’
end and subsequently slices the passenger
strand to encourage its ejection [20]. 
Structural, biochemical, and computa-
tional studies of RISC in complex with the
guide-target duplex provide rationale for the
specificity of slicer activity. In this complex,
guide strand bases 2-8 (from the 5’ end) are
uncovered and free to participate in Watson-
Crick base-pairing with the mRNA target.
This “seed region,” as it is known, is essential
for specific target recognition and places the
target’s scissile phosphate group at the slicer
active site [21]. Meanwhile, base-pairing be-
tween guide and target at nucleotides 10-11
has similarly been shown to be crucial for
properly  orienting  the  scissile  phosphate
group for slicer cleavage, explaining the fixed
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figure 2. a closer look at the model for siRna guide-strand tethering by aGo2 and
target-mRna recognition and slicing. The terminal 5’ monophosphate group of the
guide strand tucks in between the MID and PIWI domains of AGO2. Meanwhile, AGO2’s
PAZ domain has a hydrophobic pocket that specifically recognizes the guide-strands 3’
dinucleotide overhang. This positioning opens up siRNA guide nucleotides 2-8, the “seed
region,” for base pairing with complementary target mRNA, and next base pairing at nu-
cleotides 10-11 correctly orients the scissile phosphate between these two for cleavage by
AGO2’s PIWI domain, which houses the protein’s “slicer” activity [12].distance at which slicing takes place with re-
spect to the guide’s 5’end (Figure 2) [22].
RNAi machinery also can be engaged
by endogenously encoded short RNA mole-
cules known as microRNAs (miRNAs) [23].
The initial precursors of miRNAs, pri-miR-
NAs are generated in the nucleus where they
are processed by RNase III-family enzyme
Drosha to yield pre-miRNAs with a hairpin
structure (two base-paired arms linked by a
loop), a 5’ phosphate group, and a 3’ two-
nucleotide. Pre-miRNAs are then exported
into the cytoplasm, where they are further
cleaved by Dicer to remove the loop and
produce a duplex with the same characteris-
tic termini as siRNAs that is then loaded into
RISC [24]. Unlike siRNAs, however, miR-
NAs are only partially complementary to
their target mRNAs’ 3’UTR region. MiR-
NAs regulate their targets via all four Arg-
onaute  proteins,  and  while  they  can
sometimes bring about mRNA cleavage and
degradation like siRNAs, they primarily ac-
complish  gene  silencing  through  down-
stream translational repression and mRNA
decay by deadenylation [25]. 
RNAi Potential 
The power of RNAi lies in the key dis-
covery that endogenous RNAi gene silenc-
ing machinery can be hijacked to artificially
regulate genes of interest. RISC is triggered
with the introduction of an active RNAi ef-
fector, and delivery of such an effector to a
cell brings about potent and specific knock-
down of its target. Theoretically, siRNAs can
be designed for any gene of interest based on
its mRNA sequence alone. Such unlimited
potential has made RNAi a favorite gene
knockdown  strategy  in  mammalian  cells
[26]. And more importantly, RNAi-based si-
lencing potentially can be applied to design a
powerful line of therapeutics for the vast
number of human diseases caused by one or
a few genes, such as genetic defects, viral
diseases, autoimmune disorders, and cancers
[26]. Furthermore, while miRNAs are not
targetable to genes of choice the way siRNAs
are, many endogenous miRNAs function as
oncogenes and thus themselves may serve as
therapeutic targets [27].
Potency is a tremendous consideration
in drug design, and another advantage of
RNAi is that it is significantly more potent
than other nucleic acid-based antisense tech-
nologies [28]. Due to the fact that a single
siRNA guide strand can be recycled for sev-
eral rounds of mRNA cleavage, the RNAi
pathway can achieve surprising efficiency
given the right trigger. The efficiency of
RNAi mediated silencing for any particular
gene can vary greatly, and a number of fac-
tors are involved in the efficacy of any given
siRNA. RNAi makes use of a complicated,
endogenous, biological process that is con-
tingent on a number of specific interactions
between effector molecules and natural ma-
chinery. Clear understanding of these inter-
actions is indispensible to siRNA design,
and while features such as thermodynamic
end stability [29], target accessibility [30],
position-related characteristics, and other
structural features [41] are known to play a
role [26,31-33], current knowledge is still
limited. Better understanding of these fea-
tures may someday lead to super-active siR-
NAs requiring less target-site accumulation
of the siRNA, which can be a challenge [26].
challenGes of TheRaPeuTic
siRna
The therapeutic application of siRNA is
extremely promising due to efficient and
specific gene silencing, as demonstrated in
selected in vitro and in vivo studies. How-
ever, to be generally applicable, a number of
intracellular and extracellular barriers still
need to be overcome to harness the full po-
tential of this technology. 
siRNA Stability and Targeting 
Extracellularly, siRNAs are highly sus-
ceptible to degradation by enzymes found in
serum and tissues. The half-life of naked
siRNAs in serum ranges from several min-
utes to an hour [34]. As a result, target-site
accumulation to therapeutically appropriate
levels is a major challenge [35]. To be ef-
fective in a disease-relevant setting, siRNAs
must not only survive in the serum, but also
reach their target cells in the specific tissues
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interest. Then having reached their target
cells, siRNAs still face a number of hurdles
before they can exert their gene silencing ac-
tivity. The large size and negative charge of
naked siRNAs thwarts their diffusion across
the plasma membrane and prevents intracel-
lular accumulation. Meanwhile, siRNA de-
livery  strategies  that  take  advantage  of
endocytosis also must provide for endoso-
mal escape. And even once in the cell cyto-
plasm,  siRNAs  remain  vulnerable  to
degradation by intracellular RNAses and
still need to be recognized by and incorpo-
rated into RISC with high efficiency.
Off-Target Silencing 
Leaving aside the problems of delivery,
the RNAi paradigm of specific silencing un-
fortunately breaks down somewhat in reality
[26]. Microarray analysis has revealed that
siRNA  treatment  can  result  in  off-target
gene silencing, i.e., suppression of genes
other than the desired gene targets [36]. Off-
target silencing is undesirable as it can lead
to dangerous mutation of gene expression
and unexpected cell transformation. Recent
studies have demonstrated that most off-tar-
get silencing is a result of homology with six
to seven nucleotides in the “seed region” of
the siRNA sequence [37,38]. This makes
sense in the context of what is known about
miRNA gene silencing. Recall that these
constructs exert their silencing activity hav-
ing only partial sequence complementarity
(~6-8 nucleotides) with the 3’UTR of their
mRNA targets [38]. In addition, because
mRNA degradation is only one of several
ways in which miRNAs affect gene expres-
sion, some of which are at the level of trans-
lational repression, experimental screens for
off-targets that focus exclusively on analyz-
ing  mRNA  levels  may  miss  genes  sup-
pressed during translation rather than by
means of mRNA degradation [26]. Still fur-
ther, some siRNA sequences may cause al-
tered  gene  expression  because  of  “seed
region” complementarity with endogenous
miRNAs, which themselves regulate a fam-
ily of genes [26]. Poor selection of guide
strand over passenger strand by RISC can
further lead to an even higher probability of
matching undesired targets for an siRNA du-
plex. Off-target silencing cannot be ignored
in  developing  siRNA-based  therapeutics,
and all potential therapeutic siRNA candi-
date sequences must be heavily tested for
perturbation of normal protein expression
profiles. Also, as our knowledge of siRNA
mechanism advances, predictive bioinfor-
matic approaches implemented at the stage
of siRNA design promise to significantly re-
duce and eventually eradicate off-target si-
lencing. 
Activation of Immune Response
Though  largely  well-tolerated,  espe-
cially compared to long dsRNAs, siRNAs
can, in some cases, trigger an immune re-
sponse.  A  recent  report  by  Dharmacon
demonstrates that siRNA duplexes 23 nu-
cleotides long can activate interferon re-
sponses and cause cell death in culture [39].
Another recent study shows that certain siR-
NAs can bind to and activate Toll-like re-
ceptor  7  (TLR7)  if  they  contain  the
professed  “danger  motif”  (5’-GUCCUU-
CAA-3’) or similar GU-rich sequences that
also can be recognized by TLR7 [40]. Be-
cause immune reactions can vary among dif-
ferent cell types, it is difficult to anticipate
all in vivo responses based on in vitro work.
Understandably, immunogenicity and toxi-
city are grounds for concern that must be ad-
dressed in developing RNAi for therapeutic
use.
siRna DeliveRy
A potent gene-silencing agent has no
utility if it cannot be delivered to its intended
cell type, tissue, or organ. Delivery of ge-
netic material in vivo is the biggest obstacle
faced  by  siRNA  therapies  [26,34].  And
virus-based  delivery  systems,  while  effi-
cient, may be fatally flawed due to the safety
concerns they raise as they induce mutations
and trigger immunogenic and inflammatory
responses [42]. As a result, extensive work
has been done to develop efficacious non-
viral  delivery  systems,  including  direct
chemical modification of siRNA, liposome
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moieties.  These  novel  strategies  provide
ways to safely overcome obstacles facing
siRNA.
Chemical Modification
Chemical  modifications  can  signifi-
cantly enhance the stability and uptake of
naked siRNAs [43]. Importantly, siRNAs
can be directly modified without crippling
their ability to silence their targets [43].
Chemical  modifications  have
been rigorously investigated for
virtually every part of siRNA
molecules, from the termini and
backbone  to  the  sugars  and
bases, with the goal of engineer-
ing siRNA with prolonged half-
life  and  increased  cellular
uptake.  Most  commonly,  the
sugar moiety is modified. For
example, the incorporation of a
2’-fluoro  (2’-F)  [44],  2’-O-
methyl  [45],  2’-halogen,  2’-
amine [46], or 2’-deoxy [47] can
significantly increase the stabil-
ity of siRNA in serum, as can
the bridging of the sugar’s 2’-
and 4’-positions with a –O-CH2
linker (producing what is called
a “locked nucleic acid” or LNA)
(Figure 3a) [48]. Among these,
only the 2’-F can be introduced
through endogenous transcrip-
tion as opposed to chemical syn-
thesis. Another  caveat  is  that
when the sugars of both strands
of an siRNA duplex are replaced
with 2’-O-methyl moieties, the
duplex loses its silencing ability.
However, 2’-O-methyl modifi-
cation of only the sense strand
leaves silencing activity intact as
long as certain positions in the
“seed” region of the sense strand
are not modified [49]. Also, re-
cent  studies  have  shown  that
while  heavy  modification  of
siRNA  duplexes  with  LNAs
prolongs half-life in serum to as
much as 90 hours, this is not
without adverse affects on the gene-silenc-
ing  activity,  suggesting  that  the  natural
RNAi machinery can only accommodate
moderate alterations of the chemical struc-
ture of siRNAs [50].  
Backbone modifications in siRNA du-
plexes can protect against nucleases in both
the  serum  and  cytoplasm.  For  example,
modifying  the  internucleotide  phosphate
linkage in siRNA with phosphothioate (P =
S) (Figure 3a) results in moderate stability
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figure 3. a) Common chemical modifications to siRNA
sugars and backbone. B) Chemical modifications to nu-
cleobases.improvement in a nuclease-containing mi-
lieu [43], while facilitating cellular uptake
and preserving silencing function [51]; this
is not without problems, as, in some cases, P
= S substitution causes cytotoxicity [52].
Perhaps a better choice is modification of
the backbone with boranophosphate (P = B)
(Figure 3a), which enhances nuclease resist-
ance by more than 10-fold as compared to
unmodified constructs, without causing cy-
totoxicity or damage to siRNA silencing
function [53].
A number of modifications to siRNA
nucleobases have been explored with vari-
able  success.  Replacement  with  5-(3-
aminoally)-uridine  residues  eradicates
gene-silencing activity, whereas 4-thiouri-
dine and 5-bromouridine modified duplexes
remain functional [35,54]. Other common
nucleobase modifications, such as 5-iodouri-
dine, N-3-Me-uridine, and 2,6-diaminop-
urine residues (Figure 3b), can
be tolerated if they are on the
passenger strand or terminal
area of the siRNA duplex, but
not on the guide strand or seed
region of the siRNA [55]. In-
terestingly, siRNA seed region
nucleotides 2-8 (from the 5’
end of the guide) can be re-
placed with DNA nucleotides
without adversely affecting si-
lencing activity [55].
Modification  of  siRNA
termini can be used for tuning
pharmacokinetic properties, as
well as for imparting new func-
tionalities to siRNA duplexes.
Tagging the ends of siRNAs
with moieties such as choles-
terol, folate, various peptides,
and aptamers can aid in trans-
port across cellular barriers or
targeting to specific cells and
organs (also see section Target-
ing) [56,57]. Likewise, fluores-
cent molecules can be attached
to study siRNA biodistribution
and uptake [35]. These modifi-
cations must preserve certain
characteristics of the 5’ and 3’
ends of siRNAs. In particular, the 5’-phos-
phate group on the sense strand is necessary
for gene silencing by RNAi. However, ter-
minal modifications that leave the 5’-phos-
phodiester  intact  are  able  to  retain  their
silencing ability [58]. Consequences of in-
cluding modifications at the 3’-end are less
consistent and depend on the particular mod-
ification [58]. For example, 3’-biotin has no
adverse effects on silencing, whereas 3’-2-
hydroxyethyl phosphate abolishes silencing
activity [58]. SiRNAs containing 3’-ends
with  dinucleotide  overhangs  that  mimic
Dicer cleavage products are substantially
more stable and efficient than those without;
thus, most currently used synthetic siRNAs
are made with 3’ overhangs [58].
Liposomes
Loading siRNA cargo into liposomes —
vesicles consisting of a phospholid bilayer that
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figure 4. schematic of siRna nanocarriers. a) Lipo-
somes. B) Polymeric nanoparticles. c) Metallic core
nanoparticles. D) Dendrimers. e) Polymeric micelles. circumscribes an inner aqueous compartment
— is a prominent strategy for delivery to tar-
get cells (Figure 4a). Developed early on in
the pursuit of an efficient non-viral delivery
approach, these vectors have since been rig-
orously explored and characterized [59]. Li-
posomes facilitate efficient internalization of
their siRNA cargo via membrane fusion with
the host cell [42]. Lipid encapsulation is an at-
tractive delivery approach because of the bio-
compatibility of the constituents and facile
assembly of the complexes, which requires
only mixing and incubation of components
[35]. In addition, these complexes can be en-
gineered for specific delivery through conju-
gation of targeting moieties directly to the
lipid molecules prior to liposome production.
Neutral lipids are highly non-toxic and do not
activate an immune response. 1,2-Oleoyl-sn-
Glycero-3-phosphocholine (DOPC) and 1,2-
Dioleoyl-sn-Glycero-3-phosphoethanolamine
(DOPE) are among the most widely used neu-
tral lipids. Simply mixing siRNA with DOPC
results in more than 65 percent encapsulation,
and these complexes have been shown to
bring about siRNA-mediated silencing in can-
cer cells in vivo[60]. Generally, however, neu-
tral liposomes yield relatively low transfection
efficiency. Cationic lipids, such as 1-oleoyl-2-
[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)
amino]hexanoyl]-3-trimethylammonium
propane (DOTAP), can complex electrostati-
cally with siRNAs and be used to create a
more  effective  liposome  as  the  positively
charged lipids provide enhanced cell entry and
increased protection against serum enzymes
[61]. But incorporation of positive charge to
increase transfection efficiency must be care-
fully balanced against inflammatory effects
that the polycations create in vivo, as well as
unwanted interaction with negatively charged
serum proteins, which can lead to opsoniza-
tion and clearance of the lipocomplex [62].
Recently, a new wave of work in lipid-
based delivery systems has demonstrated
that  some  synthetic  lipid-like  materials
(termed “lipidoids”) form complexes with
siRNA or miRNA that facilitate intracellu-
lar delivery of the oligonucleotides [100]. In
fact, lipidoids that are individually ineffec-
tive at delivering siRNA become surpris-
ingly effective when formulated together as
binary combinations into single delivery ve-
hicles [63]. The rationale behind the synergy
of certain combinations of materials is that
while neither individual component material
is capable of mediating every part of siRNA
delivery (i.e., cellular entry, endosomal es-
cape), each may facilitate one distinct step
and  together  may  be  able  to  accomplish
complete delivery [63]. The discovery of
synergy among materials significantly ex-
pands the material space available for engi-
neering a therapeutic delivery system and
may produce important systems for siRNA
delivery. 
Nanoparticles
Polymeric nanoparticles are promising
gene delivery systems because they offer
stability and controlled release, have the ca-
pacity to encapsulate large amounts of ge-
netic material, allow for co-delivery, and can
readily be surface-modified to enhance sta-
bility, transport properties, targeting, or up-
take.  Polymers  that  are  biodegradable,
biocompatible, and non-toxic make attrac-
tive candidates for constructing in vivo de-
livery  vehicles.  Chitosan,  cyclodextrin,
polyethyleneimine (PEI), poly(lactic-co-gly-
colic) acid (PLGA), dendrimers, and metal-
lic core nanoparticles have become popular
for use in delivery systems, although none
of these materials possess all of the desirable
properties [35,42]. 
Chitosan is a natural, cationic polysac-
charide  harvestable  from  crustacean  ex-
oskeletons.  It  is  an  extensively  studied
biomaterial due to its biocompatibility, mu-
coadhesive properties, and nuclease resist-
ance [35,64]. Optimal cationic charge for
maximal siRNA encapsulation in chitosan
can be attained by tuning the ratio of amines
to phosphates (N:P). In two separate studies,
optimized  chitosan-siRNA  nanoparticles
have  been  successfully  administered  in-
tranasally to silence GAPDH and EGFP in
the lungs of mice [65,66].
Cyclodextrin-based polycations (CDPs)
are another class of highly non-toxic poly-
mer-based complexes used to deliver siR-
NAs, as well as other therapeutic compounds
194 Gavrilov and Saltzman: Therapeutic siRNAsuch as plasmids and small molecule drugs.
These constructs consist of cationic polymer
complexed with siRNA duplexes and inter-
digitated with funnel-like cyclodextrin mol-
ecules,  which,  in  turn,  can  be  linked  to
functionalized adamantane molecules [35].
Impressive in vivo results were recently re-
ported with siRNA-loaded CDPs functional-
ized  with  adamantane-transferrin  and
adamantane-PEG.  Functionalized  CDPs
loaded with siRNAs targeting fusion onco-
protein  EWS-FLI1  were  administered  to
non-human primates and demonstrated to
bring about shrinkage of implanted tumors
[67]. Significantly, early results also suggest
that these materials can produce RNAi in hu-
mans [98]. 
Extensive branching and dense cationic
charge gives synthetic polymer polyethyl-
eneimine (PEI) the capacity to condense siR-
NAs,  protect  them  from  degradation  by
RNases, and facilitate their cellular uptake via
endocytosis [68]. An added feature is the abil-
ity of PEI to act as a proton sponge, because
its extensive amine groups buffer the acidic
inner compartment of an endosome causing
water to swell the endosome to the point of
rupture, thereby facilitating endosomal es-
cape of its encapsulated siRNA [35]. Some
wariness surrounds PEI use in vivo, however,
due to in vitro evidence of high cytotoxicity
[69]. In an effort to reduce toxic effects of
PEI, the polymer has been modified with
polyethylene  glycol  (PEG)  (previously
demonstrated to slow clearance and reduce
toxicity) and the PEI-PEG/siRNA complex
shown to exhibit decreased toxicity, but dras-
tically increased particle size [70].  
The degradable polymer PLGA is another
attractive choice for siRNA encapsulation to-
ward in vivo delivery of siRNA. FDA-ap-
proved PLGA breaks down by hydrolysis of
its ester bonds into lactic and glycolic acids —
natural metabolic breakdown products of the
body. In addition to the biocompatibility ad-
vantage, PLGA also can be easily assembled
into a carrier system for large amounts of
siRNA that offers controlled and sustained re-
lease [71]. PLGA nanoparticles (~100nm in di-
ameter) are capable of achieving intracellular
delivery of DNA plasmids [72], siRNAs [71],
and chemotherapeutic agents [73]. Still further,
PLGA nanoparticles are favorable siRNA de-
livery systems because they can readily be sur-
face-modified to enhance targeting or uptake
[97,99].
Dendrimers are heavily branched poly-
meric molecules that can be engineered to
form modular, nano-sized, spherical stru-
tures for siRNA delivery (Figure 4d). Pack-
aging siRNAs in dendrimer structures can
be accomplished by positively charging the
core while abolishing surface charge [74].
Alternatively, siRNAs can be caged within
dendrimer polyplexes via disulfide linkages,
which  incidentally  also  provide  for  con-
trolled release in the reducing intracellular
milieu. These structures can be additionally
stabilized through the incorporation of PEG
[75]. The modularity of dendrimers allows
for dendrimer-siRNA polyplexes to be fur-
ther improved for siRNA delivery by com-
bining  them  with  targeting  ligands  and
technologies that provide for endosomal re-
lease [76].
Polymeric micelles share some charac-
teristics  with  liposomes  and  polymeric
nanoparticles, providing the stealth proper-
ties  of  liposomes  with  their  hydrophilic
shells while simultaneously offering protec-
tive stability within their hydrophobic cores
(Figure 4e) [77,79]. These self-assembled
nanostructures  composed  of  amphiphilic
block copolymers can be tuned for siRNA
delivery by grafting them with amines that
can complex siRNA. Alternatively, siRNA
can be “reversibly” conjugated to the am-
phiphilic polymers through disulfide bonds,
which are then reduced intracellularly to re-
lease the siRNA [80]. The ability of poly-
meric micelles to both remain stable through
dilution  in  biological  fluids  and  shelter
siRNA from degradation makes them prom-
ising carriers for therapeutic development
[77].
Another siRNA delivery strategy in-
volves metallic core nanoparticles (Figure
4c) [83]. Metal cores of iron oxide, iron
cobalt, iron gold, or iron nickel are coated
with a layer of sugars or other polymers gen-
erating  a  core-shell  structure  to  which
siRNA can be externally conjugated through
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tran [79], cationic polymers [80,82], or bi-
otin-streptavadin [35]. Contingent upon the
metal used, the cores of these particles can
impart properties that allow for study of
biodistribution upon injection using mag-
netic resonance imaging or targeting to spe-
cific tissues by applying external magnets.
These systems provide unique advantages
other approaches lack, but in vivo toxicity
may prove prohibitory. More recently, mul-
tifunctional platforms, such as iron oxide
nanoparticles-dendrimer  complexes  [81],
have  been  shown  to  effectively  deliver
siRNA  in  vivo representing  headway  of
novel combinatorial strategies.
Targeting
Selectively  targeting  siRNAs  to  dis-
eased cells or tissues increases accumulation
of the therapeutic at the site of interest, in-
creasing the silencing potency, thereby mak-
ing a given treatment dose more effective.
In addition, targeting to cells adds another
layer of specificity: avoiding off-target ef-
fects by decreasing the probability of uptake
by healthy cells. A common drug delivery
strategy for targeting cells of interest is con-
jugation to ligands such as antibodies, ap-
tamers, small molecules, and peptides that
specifically interact with corresponding sur-
face moieties of target cells [90,91]. 
Antibodies have been widely used for
targeting in a number of drug delivery appli-
cations. Popular for their specificity, diversity,
and ability to modulate biodistribution, anti-
bodies against targets ranging from oncogenes
such as HER2 [84] to HIV envelope proteins
[29] have been appended to nanoparticles for
in vivotarget-site delivery. An unfortunate dif-
ficulty of this approach is the large size of an-
tibody targeting moieties, which can make
them difficult to conjugate to particle surfaces
at high concentrations. And if translated to the
clinics, long-term administration of treatment
may be limited by immune responses to the
targeting reagent. However, incorporation of
humanized antibodies may provide the solu-
tion to this problem.
As an alternate to antibodies, aptamers
have been explored for targeted siRNA de-
livery. Aptamers are able to bind their re-
spective ligand molecules with an affinity
and specificity on the same scale as anti-
body-antigen partners, but without recogni-
tion by native antibodies, which makes them
more  amenable  to  long-term  treatment
schedules [35]. However, the number of ap-
tamers known to bind targets that are mark-
ers for disease is extremely limited. And
moreover, aptamer binding to targets does
not always lead to cargo internalization [35].
Aptamer-based targeting may become more
widespread as more aptamers for disease-
relevant are targets are discovered.
Cholesterol  and  its  derivatives  have
been effectively employed as targeting lig-
ands. The surfaces of hepatocytes are heav-
ily  populated  with  cholesterol  receptors,
which internalize cholesterol through endo-
cytosis [85,86]. This property has been used
for liver-targeting. In a notable study, siRNA
against  apolipoprotein  B  (apoB)  was  di-
rectly conjugated to cholesterol and admin-
istered intravenously in mice. The constructs
were shown to accumulate in the liver and
to reduce apoB levels by more than 57 per-
cent [87]. In addition to targeting, choles-
terol conjugation has been shown to impart
generally desirable “drug-like” properties
such as stability and bioavailability.
Folate  receptors  are  highly  overex-
pressed in a number of cancers but are vir-
tually absent in all other normal tissues, with
the exception of the kidneys [88,89]. Active
folate receptor facilitates cellular uptake of
folate  compounds  and  folate  conjugates
[92]. Its abilities to mediate internalization
and its narrow expression range make it an
attractive surface target, and conjugating fo-
late to the surface of particles has become a
common strategy in cancer drug delivery
[93]. Similarly to folate receptors, some can-
cer cells overexpress surface receptors re-
sponsive to larger protein ligands such as
transferrin. SiRNA-loaded particles conju-
gated with transferrin moities have been
shown to preferentially accumulate in cer-
tain metastasized tumors and bring about
significant reduction of tumor growth in
mice and have been successfully tested in
non-human primates [94,95].
196 Gavrilov and Saltzman: Therapeutic siRNAA general surface modification shown
to be tremendously effective in a wide vari-
ety of systems is the attachment of a poly-
ethylene  glycol  (PEG)  moiety.  PEG  has
been shown to generally reduce toxicity and
slow clearance from the blood, thereby pro-
foundly prolonging half-life and bioavail-
ability  and  allowing  for  longer-term
treatment administration and resulting in an
overall increase in drug activity achieved
[96]. Extension in half-life of materials in
the circulation can improve passive target-
ing to tumors by the enhanced permeability
and retention (EPR) effect [101,102].
Although small, nanoparticles are gen-
erally  too  large  to  easily  transverse  the
plasma membrane. Cell membrane translo-
cation can be facilitated by conjugating cell-
penetrating  peptides  (CPPs)  to  the
nanoparticle  surface  to  aid  transduction.
Well-studied CPPs penetratin (ANTP) and
TAT have been demonstrated to significantly
enhance uptake in a number of applications
[97]. Further, there is evidence for a syner-
gistic effect between these CPPs and folate,
which may also be found among other com-
binations of surface moieties [97].
conclusion 
The discovery of siRNAs — constructs
that can be designed to specifically and effi-
ciently  silence  genes  of  interest  —  has
stirred considerable excitement. Most excit-
ing is the potential therapeutic application of
this technology. Though a number of chal-
lenges stand in the way of realizing this po-
tential,  the  biggest  bottleneck  in  siRNA
delivery, over a decade of innovative engi-
neering has resulted in solutions to a number
of these challenges, laying down a founda-
tion for continuing headway toward making
widespread  therapeutic  siRNA  a  reality
hopefully in the not too distant future.
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